Download PDF
Semin Neurol 2007; 27(4): 312-324
DOI: 10.1055/s-2007-985333
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Brain Tumors: Current Issues in Diagnosis and Management

Mark K. Lyons1 , Sujay A. Vora2
  • 1Department of Neurological Surgery, Mayo Clinic Arizona, Phoenix, Arizona
  • 2Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona
Further Information

Publication History

Publication Date:
15 August 2007 (online)

    Permissions and Reprints

ABSTRACT

There has been significant progress made in the diagnosis and treatment of brain tumors over the past 15 years. This has largely been due to significant advances in radiographic imaging capabilities that have allowed for much earlier detection of disease, both new and recurrent. Advances in surgical and radiotherapy techniques and technology have also affected the care of these patients. More recent advances in chemotherapy options and double and triple crossover clinical trials are beginning to have an impact in the treatment of malignant brain tumors. This article will address the 4 most common brain tumors practicing physicians see and will review the current concepts in treating these tumors.

KEYWORDS

Meningioma - glioma - brain tumor - diagnosis and treatment

REFERENCES

  • 1 Central Brain Tumor Registry of the United States (CBTRUS). Available at: http://www.cbtrus.org/2002/2002products.htm. Accessed 2006
    Google Scholar
  • 2 Surawicz T S, McCarthy B J, Kupelian V, Jukich P J, Bruner J M, Davis F G. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.  Neuro Oncol. 1999;  1 14-25
    PubMedGoogle Scholar
  • 3 Bondy M, Ligon B L. Epidemiology and etiology of intracranial meningiomas: a review.  J Neurooncol. 1996;  29 197-205
    CrossrefPubMedGoogle Scholar
  • 4 Claus E B, Bondy M L, Schildkraut J M, Wiemels J L, Wrensch M, Black P M. Epidemiology of intracranial meningiomas.  Neurosurgery. 2005;  57 1088-1095
    CrossrefPubMedGoogle Scholar
  • 5 Kalkanis S N, Quinones-Hinojosa A, Buzney E, Ribaudo H J, Black P M. Quality of life following surgery for intracranial meningiomas at Brigham and Women's Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire.  J Neurooncol. 2000;  48 233-241
    CrossrefPubMedGoogle Scholar
  • 6 Kondziolka D, Levy E I, Niranjan A, Flickinger J C, Lunsford L D. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives.  J Neurosurg. 1999;  91 44-50
    CrossrefPubMedGoogle Scholar
  • 7 De Jesus O, Sekhar L N, Parikh H K, Wright D C, Wagner D P. Long-term follow-up of patients with meningiomas involving the cavernous sinus: recurrence, progression, and quality of life.  Neurosurgery. 1996;  39 915-919
    PubMedGoogle Scholar
  • 8 Longstreth W T, Dennis L K, McGuire V M, Drangsholt M T, Koepsell T D. Epidemiology of intracranial meningioma.  Cancer. 1993;  72 639-648
    CrossrefPubMedGoogle Scholar
  • 9 Hardell L, Nasman A, Pahlson A, Hallquist A, Hansson M K. Use of cellular telephones and the risk for brain tumors: a case/control study.  Int J Oncol. 1999;  15 113-116
    PubMedGoogle Scholar
  • 10 Johansen C, Boice J, McLaughlin J, Olsen J. Cellular telephones and cancer: a nationwide cohort study in the United States, 1985-1994.  J Natl Cancer Inst. 2001;  93 203-207
    CrossrefPubMedGoogle Scholar
  • 11 Dreyer N A, Loughlin J E, Rothman K J. Cause-specific mortality in cellular telephone users.  JAMA. 1999;  282 1814-1816
    CrossrefPubMedGoogle Scholar
  • 12 Rothman K J, Loughlin J E, Fuch D P, Dreyer N A. Overall mortality of cellular telephone customers.  Epidemiology. 1996;  7 303-305
    PubMedGoogle Scholar
  • 13 Schlehofer B, Blettner M, Preston-Martin S et al.. Role of medical history in brain tumor development: results from the International Adult Brain Tumor Study.  Int J Cancer. 1999;  82 155-160
    CrossrefPubMedGoogle Scholar
  • 14 Brenner A V, Linet M S, Fine H A et al.. History of allergies and autoimmune diseases and risk of brain tumors in adults.  Int J Cancer. 2002;  99 252-259
    CrossrefPubMedGoogle Scholar
  • 15 Schuz J, Boher E, Berg G et al.. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany).  Am J Epidemiol. 2006;  163 512-520
    CrossrefPubMedGoogle Scholar
  • 16 Morgan L L. Letter to the editor: Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany).  Am J Epidemiol. 2006;  164 294-295
    CrossrefPubMedGoogle Scholar
  • 17 Donnell M S, Meyer G A, Donegan W L. Estrogen-receptor protein in intracranial meningioma.  J Neurosurg. 1979;  50 499-502
    PubMedGoogle Scholar
  • 18 Black P M. Meningiomas.  Neurosurgery. 1993;  32 643-657
    CrossrefPubMedGoogle Scholar
  • 19 Carroll R S, Zhang J, Black P M. Expression of estrogen receptors alpha and beta in human meningiomas.  J Neurooncol. 1999;  42 109-116
    CrossrefPubMedGoogle Scholar
  • 20 Hsu D W, Efrid J T, Hedley-Whyte E T. Progesterone and estrogen receptors in meningiomas: prognostic considerations.  J Neurosurg. 1997;  86 113-120
    CrossrefPubMedGoogle Scholar
  • 21 Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades H N. Expression of androgen and progesterone receptors in primary human meningiomas.  J Neurosurg. 1993;  78 456-462
    PubMedGoogle Scholar
  • 22 Chen J, Chen G. Expression of androgen receptor in meningiomas.  J Tongji Med Univ. 2001;  21 140-142
    PubMedGoogle Scholar
  • 23 Jhawar B S, Colditz G, Fuchs C, Stampfer M. Sex hormone exposures and risk for meningiomas.  J Neurosurg. 2003;  99 848-853
    CrossrefPubMedGoogle Scholar
  • 24 Busch D. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management.  Int J Radiat Oncol Biol Phys. 1994;  30 997-1002
    PubMedGoogle Scholar
  • 25 Wrensch M, Minn Y, Chew T, Bondy M, Berger M. Epidemiology of primary brain tumors: current concepts and review of the literature.  Neuro Oncol. 2002;  4 278-299
    PubMedGoogle Scholar
  • 26 Ron E, Modn B, Boice J D et al.. Tumors of the brain and nervous system after radiotherapy in childhood.  N Engl J Med. 1988;  319 1033-1039
    CrossrefPubMedGoogle Scholar
  • 27 Longstreth W T, Phillips L E, Drangsholt M T et al.. Dental x-rays and the risk of intracranial meningioma.  Cancer. 2004;  100 1026-1034
    CrossrefPubMedGoogle Scholar
  • 28 Bateman B T, Pile-Spellman J, Gutin P H, Berman M F. Meningioma resection in the elderly: nationwide inpatient sample, 1998-2002.  Neurosurgery. 2005;  57 866-872
    CrossrefPubMedGoogle Scholar
  • 29 Saberi H, Meybodi A T, Rezai A S. Levine-Sekhar grading system for prediction of the extent of resection of cranial base meningiomas revisited: study of 124 cases.  Neurosurg Rev. 2006;  29 138-144
    PubMedGoogle Scholar
  • 30 Goldsmith B J, Wara W M, Wilson C B et al.. Postoperative irradiation for subtotally resected meningiomas: a retrospective analysis of 140 patients treated from 1967-1990.  J Neurosurg. 1994;  80 195-201
    CrossrefPubMedGoogle Scholar
  • 31 Modha A, Gutin P H. Diagnosis and treatment of atypical and anaplastic meningiomas: a review.  Neurosurgery. 2005;  57 538-550
    CrossrefPubMedGoogle Scholar
  • 32 Cusimano M D, Sekhar L N, Sen C N et al.. The results of surgery for benign tumours of the cavernous sinus.  Neurosurgery. 1995;  37 1-10
    PubMedGoogle Scholar
  • 33 Chin L S, Szerlip N J, Regine W F. Stereotactic radiosurgery for meningiomas.  Neurosurg Focus. 2003;  14 e6
    PubMedGoogle Scholar
  • 34 Torres R C, Frighetto L, De Salles A A et al.. Radiosurgery and stereotactic radiotherapy for intracranial meningiomas.  Neurosurg Focus. 2003;  14 e5
    PubMedGoogle Scholar
  • 35 Olson J D, Riedel E MA, DeAngelis L M. Long-term outcome of low-grade oligodendroglioma and mixed astrocytoma.  Neurology. 2000;  54 1442-1448
    PubMedGoogle Scholar
  • 36 Rutka J T, Weyerbrock A, Liang M L. Gliomas: Quo Vadis. .  Clin Neurosurg. 2006;  53 58-63
    PubMedGoogle Scholar
  • 37 Walker D G, Kaye A H. Low grade glial neoplasms.  J Clin Neurosci. 2003;  10 1-13
    CrossrefPubMedGoogle Scholar
  • 38 Paleologos N A. Chemotherapy for low-grade gliomas.  Expert Rev Neurother. 2005;  5 S21-S24
    CrossrefPubMedGoogle Scholar
  • 39 Mehta N, Silverberg W. Role of radiotherapy in the treatment of gliomas.  Expert Rev Neurother. 2005;  5 S51-S61
    CrossrefPubMedGoogle Scholar
  • 40 Cavaliere R, Lopes M BS, Schiff D. Low-grade gliomas: an update on pathology and therapy.  Lancet Neurol. 2005;  4 760-770
    PubMedGoogle Scholar
  • 41 Daumas-Duport C, Scheithauer B W, O'Fallon J, Kelly P J. Grading system of astrocytomas: a simple and reproducible method.  Cancer. 1988;  62 2152-2165
    CrossrefPubMedGoogle Scholar
  • 42 Lyons M K, Kelly P J. Computer-assisted stereotactic biopsy and volumetric resection of thalamic pilocytic astrocytomas: report of 23 cases.  Stereotact Funct Neurosurg. 1992;  59 100-104
    PubMedGoogle Scholar
  • 43 Lyons M K. Pilocytic astrocytoma with spontaneous intracranial hemorrhages in an elderly adult.  Clin Neurol Neurosurg. 2007;  109 76-80
    CrossrefPubMedGoogle Scholar
  • 44 Laws E R, Taylor W F, Clifton M B, Okazaki H. Neurosurgical management of low grade astrocytoma of the cerebral hemispheres.  J Neurosurg. 1984;  61 665-673
    PubMedGoogle Scholar
  • 45 Shaw E G, Scheithauer B W, O'Fallon J R, Davis D H. Mixed oligoastrocytomas: a survival and prognostic factor analysis.  Neurosurgery. 1994;  34 577-582
    PubMedGoogle Scholar
  • 46 Pignatti F, van den Bent M, Curran D. Prognostic factors for survival in adult patients with cerebral low-grade glioma.  J Clin Oncol. 2002;  20 2076-2084
    CrossrefPubMedGoogle Scholar
  • 47 Leighton C, Fisher B, Bauman G. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation.  J Clin Oncol. 1997;  15 1294-1301
    CrossrefPubMedGoogle Scholar
  • 48 Wrensch M, Minn Y, Chew T, Bondy M, Berger M S. Epidemiology of primary brain tumors: current concepts and review of the literature.  Neuro-oncol. 2002;  4 278-299
    PubMedGoogle Scholar
  • 49 Franzini A, Leocata L, Cajola L, Servello D, Allegranza A, Broggi G. Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal.  Neurosurgery. 1994;  35 817-820
    PubMedGoogle Scholar
  • 50 Scanlon P W, Taylor W F. Radiotherapy of intracranial astrocytomas: analysis of 417 cases treated from 1960 through 1969.  Neurosurgery. 1979;  5 301-308
    PubMedGoogle Scholar
  • 51 Coons S W, Johnson P C, Scheithauer B W, Yates A J, Pearl D K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.  Cancer. 1997;  79 1381-1393
    CrossrefPubMedGoogle Scholar
  • 52 Hart M N, Petito C K, Earle K M. Mixed gliomas.  Cancer. 1974;  33 134-140
    CrossrefPubMedGoogle Scholar
  • 53 Soffietti R, Chio A, Giordana M T, Vasario E, Schiffer D. Prognostic factors in well-differentiated cerebral astrocytomas in the adult.  Neurosurgery. 1989;  24 686-692
    PubMedGoogle Scholar
  • 54 Kreth F W, Faist M, Rossner R, Ostertag C B. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas: a new pattern of prognostic factors.  Cancer. 1997;  79 370-379
    CrossrefPubMedGoogle Scholar
  • 55 van den Bent M J, Afra D, de Witte O et al.. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.  Lancet. 2005;  366 985-990
    CrossrefPubMedGoogle Scholar
  • 56 Shaw E, Arusell R, Scheithauer B W. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade gliomas: initial report of a North Central Cancer treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.  J Clin Oncol. 2002;  20 2267-2276
    CrossrefPubMedGoogle Scholar
  • 57 Piepmeier J, Christopher S, Spencer D. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas.  Neurosurgery. 1996;  38 872-878
    CrossrefPubMedGoogle Scholar
  • 58 Philippon J H, Clemenceau S H, Fauchon F H, Foncin J F. Supratentorial low-grade astrocytomas in adults.  Neurosurgery. 1993;  32 554-559
    CrossrefPubMedGoogle Scholar
  • 59 Bauman G, Lote K, Larson D. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis.  Int J Radiat Oncol Biol Phys. 1999;  45 923-929
    CrossrefPubMedGoogle Scholar
  • 60 Kelly P J, Daumas-Duport C, Scheithauer B W, Kall B A, Kispert D B. Stereotactic histologic correlations of computerized tomography and magnetic resonance imaging defined abnormalities in patients with glial neoplasms.  Mayo Clin Proc. 1987;  62 450-459
    PubMedGoogle Scholar
  • 61 Keles G E, Lamborn K R, Berger M S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome.  J Neurosurg. 2001;  95 735-745
    CrossrefPubMedGoogle Scholar
  • 62 Lunsford L D, Somaza S, Kondziolka D, Flickinger J C. Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma.  J Neurosurg. 1995;  82 523-529
    PubMedGoogle Scholar
  • 63 Janny P, Cure H, Mohr M. Low grade supratentorial astrocytomas: management and prognostic factors.  Cancer. 1994;  73 1937-1945
    CrossrefPubMedGoogle Scholar
  • 64 Nicolato A, Gerosa M A, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A. Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adults.  Surg Neurol. 1995;  44 208-221
    CrossrefPubMedGoogle Scholar
  • 65 Bahary J P, Villemure J G, Choi S. Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era.  J Neurooncol. 1996;  27 173-177
    PubMedGoogle Scholar
  • 66 Leighton C, Fisher B. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation.  J Clin Oncol. 1997;  15 1294-1301
    CrossrefPubMedGoogle Scholar
  • 67 Grabenbauer G G, Roedel C M, Paulus W. Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy.  Strahlenther Onkol. 2000;  176 259-264
    CrossrefPubMedGoogle Scholar
  • 68 Berger M S, Rostomily R C. Low grade gliomas: functional mapping resection strategies, extent of resection and outcome.  J Neurooncol. 1997;  34 85-101
    PubMedGoogle Scholar
  • 69 Daumas-Duport C, Scheithauer B W, Kelly P J. A histologic and cytologic method for the spatial definition of gliomas.  Mayo Clin Proc. 1987;  62 435-449
    PubMedGoogle Scholar
  • 70 Kelly P J. Volumetric stereotactic surgical resection of intra-axial brain mass lesions.  Mayo Clin Proc. 1988;  63 1186-1198
    PubMedGoogle Scholar
  • 71 Shaw E G, Daumas-Duport C, Scheithauer B W. Radiation therapy in the management of low-grade supratentorial astrocytomas.  J Neurosurg. 1989;  70 853-861
    PubMedGoogle Scholar
  • 72 Medbery C A, Strauss S M, Steinberg J D, Cotelingam J D, Fisher W S. Low-grade astrocytomas: treatment results and prognostic variables.  Int J Radiat Oncol Biol Phys. 1988;  15 837-841
    PubMedGoogle Scholar
  • 73 Kaye A H, Walker D G. Low grade astrocytomas: controversies in management.  J Clin Neurosci. 2000;  7 475-483
    CrossrefPubMedGoogle Scholar
  • 74 Vertosick F T, Selker R G, Arena V C. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography.  Neurosurgery. 1991;  28 496-501
    PubMedGoogle Scholar
  • 75 Whitton A C, Bloom H J. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases.  Int J Radiat Oncol Biol Phys. 1990;  18 783-786
    PubMedGoogle Scholar
  • 76 Karim A B, Maat B. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.  Int J Radiat Oncol Biol Phys. 1996;  36 549-556
    CrossrefPubMedGoogle Scholar
  • 77 Imperato J P, Paleologos N A, Vick N A. Effects of treatment on long-term survivors with malignant astrocytomas.  Ann Neurol. 1990;  28 818-822
    CrossrefPubMedGoogle Scholar
  • 78 Gregor A, Cull A, Traynor E, Stewart M, Lander F, Love S. Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters.  Radiother Oncol. 1996;  41 55-59
    PubMedGoogle Scholar
  • 79 Morris D E, Bourland J D, Rosenman J G, Shaw E G. Three-dimensional conformal radiation treatment planning and delivery for low- and intermediate-grade gliomas.  Semin Radiat Oncol. 2001;  11 124-137
    CrossrefPubMedGoogle Scholar
  • 80 Eyre H J, Crowley J J, Townsend J J. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group Study.  J Neurosurg. 1993;  78 909-914
    PubMedGoogle Scholar
  • 81 Schiffer D, Dutto A. Prognostic factors in oligodendroglioma.  Can J Neurol Sci. 1997;  24 313-319
    PubMedGoogle Scholar
  • 82 Soffietti R, Ruda R, Bradac G B, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.  Neurosurgery. 1998;  43 1066-1073
    CrossrefPubMedGoogle Scholar
  • 83 Cairncross J G, MacDonald D R. Successful chemotherapy for recurrent malignant oligodendroglioma.  Ann Neurol. 1988;  23 360-364
    CrossrefPubMedGoogle Scholar
  • 84 Chahlavi A, Kanner A, Peereboom D, Staugaitis S M, Elson P, Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolimide: preliminary results.  J Neurooncol. 2003;  61 267-273
    CrossrefPubMedGoogle Scholar
  • 85 Brada M, Viviers L, Abson C. Phase II study of primary temozolimide chemotherapy in patients with WHO grade II gliomas.  Ann Oncol. 2003;  14 1715-1721
    CrossrefPubMedGoogle Scholar
  • 86 Pace A, Vidiri A, Galie E. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.  Ann Oncol. 2003;  14 1722-1726
    CrossrefPubMedGoogle Scholar
  • 87 Buckner J C, Gesme D, O'Fallon J R. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.  J Clin Oncol. 2003;  21 251-255
    CrossrefPubMedGoogle Scholar
  • 88 van den Bent M J, Taphoorn M J, Brandes A A. Phase II study of first-line chemotherapy with temozolimide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.  J Clin Oncol. 2003;  21 2525-2528
    CrossrefPubMedGoogle Scholar
  • 89 Quinn J A, Reardon D A, Friedman A H. Phase II trial of temozolimide in patients with progressive low-grade glioma.  J Clin Oncol. 2003;  21 646-651
    CrossrefPubMedGoogle Scholar
  • 90 Hoang-Xuan K, Capelle L, Kujas M. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.  J Clin Oncol. 2004;  22 3133-3138
    CrossrefPubMedGoogle Scholar
  • 91 van den Bent M J, Chinot O, Boogerd W et al.. Second-line chemotherapy with temozolimide in recurrent oligodendroglioma after PVC (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.  Ann Oncol. 2003;  14 599-602
    CrossrefPubMedGoogle Scholar
  • 92 Lim L C, Rosenthal M A, Maartens N et al.. Management of brain metastases.  Intern Med J. 2004;  34 270-278
    CrossrefPubMedGoogle Scholar
  • 93 Zimm S, Wampler G L, Stablein D et al.. Intracerebral metastases in solid-tumor patients: natural history and results of treatment.  Cancer. 1981;  48 384-394
    CrossrefPubMedGoogle Scholar
  • 94 Wen P Y, Loeffler J S. Brain metastases.  Curr Treat Options Oncol. 2000;  1 447-458
    PubMedGoogle Scholar
  • 95 Delattre J Y, Krol G, Thaler H T et al.. Distribution of brain metastases.  Arch Neurol. 1988;  45 741-744
    CrossrefPubMedGoogle Scholar
  • 96 Gaspar L, Scott C, Rotman M et al.. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.  Int J Radiat Oncol Biol Phys. 1997;  37 745-751
    Google Scholar
  • 97 Patchell R A, Tibbs P A, Walsh J W et al.. A randomized trial of surgery in the treatment of single metastases to the brain.  N Engl J Med. 1990;  322 494-500
    CrossrefPubMedGoogle Scholar
  • 98 Vecht C J, Haaxma-Reiche H, Noordijk E M et al.. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?.  Ann Neurol. 1993;  33 583-590
    CrossrefPubMedGoogle Scholar
  • 99 Patchell R A, Tibbs P A, Regine W F et al.. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.  JAMA. 1998;  280 1485-1489
    CrossrefPubMedGoogle Scholar
  • 100 DeAngelis L M, Delattre J Y, Posner J B. Radiation-induced dementia in patients cured of brain metastases.  Neurology. 1989;  39 789-796
    PubMedGoogle Scholar
  • 101 Regine W F, Huhn J L, Patchell R A et al.. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications.  Int J Radiat Oncol Biol Phys. 2002;  52 333-338
    CrossrefPubMedGoogle Scholar
  • 102 Mehta M P, Shapiro W R, Glantz M J et al.. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.  J Clin Oncol. 2002;  20 3445-3453
    CrossrefPubMedGoogle Scholar
  • 103 Stea B, Shaw E, Pinter T et al.. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.  Br J Cancer. 2006;  94 1777-1784
    CrossrefPubMedGoogle Scholar
  • 104 Abrey L E, Christodoulou C. Temozolomide for treating brain metastases.  Semin Oncol. 2001;  28 34-42
    PubMedGoogle Scholar
  • 105 Margolin K, Atkins B, Thompson A et al.. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.  J Cancer Res Clin Oncol. 2002;  128 214-218
    CrossrefPubMedGoogle Scholar
  • 106 Flickinger J C, Kondziolka D, Lunsford L D et al.. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis.  Int J Radiat Oncol Biol Phys. 1994;  28 797-802
    PubMedGoogle Scholar
  • 107 Andrews D W, Scott C B, Sperduto P W et al.. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.  Lancet. 2004;  363 1665-1672
    CrossrefPubMedGoogle Scholar
  • 108 Sneed P K, Suh J H, Goetsch S J et al.. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases.  Int J Radiat Oncol Biol Phys. 2002;  53 519-526
    CrossrefPubMedGoogle Scholar
  • 109 Aoyama H, Shirato H, Tago M et al.. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.  JAMA. 2006;  295 2483-2491
    CrossrefPubMedGoogle Scholar
  • 110 Ohgaki H, Dessen P, Jourde B et al.. Genetic pathways to glioblastoma: a population-based study.  Cancer Res. 2004;  64 6892-6899
    CrossrefPubMedGoogle Scholar
  • 111 Curran Jr W J, Scott C B, Horton J et al.. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.  J Natl Cancer Inst. 1993;  85 704-710
    PubMedGoogle Scholar
  • 112 Kreth F W, Berlis A, Spiropoulou V et al.. The role of tumor resection in the treatment of glioblastoma multiforme in adults.  Cancer. 1999;  86 2117-2123
    CrossrefPubMedGoogle Scholar
  • 113 Simpson J R, Horton J, Scott C et al.. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials.  Int J Radiat Oncol Biol Phys. 1993;  26 239-244
    PubMedGoogle Scholar
  • 114 Westphal M, Ram Z, Riddle V et al.. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.  Acta Neurochir (Wien). 2006;  148 269-275 , discussion 275
    CrossrefPubMedGoogle Scholar
  • 115 Gaspar L E, Fisher B J, Macdonald D R et al.. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment.  Int J Radiat Oncol Biol Phys. 1992;  24 55-57
    PubMedGoogle Scholar
  • 116 Kleinberg L, Slick T, Enger C et al.. Short course radiotherapy is an appropriate option for most malignant glioma patients.  Int J Radiat Oncol Biol Phys. 1997;  38 31-36
    CrossrefPubMedGoogle Scholar
  • 117 Roa W, Brasher P M, Bauman G et al.. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.  J Clin Oncol. 2004;  22 1583-1588
    CrossrefPubMedGoogle Scholar
  • 118 Loeffler J S, Alexander III E, Shea W M et al.. Radiosurgery as part of the initial management of patients with malignant gliomas.  J Clin Oncol. 1992;  10 1379-1385
    PubMedGoogle Scholar
  • 119 Loeffler J S, Shrieve D C, Alexander III E. Radiosurgery for glioblastoma multiforme: the importance of selection criteria.  Int J Radiat Oncol Biol Phys. 1994;  30 731-733
    PubMedGoogle Scholar
  • 120 Sarkaria J N, Mehta M P, Loeffler J S et al.. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group.  Int J Radiat Oncol Biol Phys. 1995;  32 931-941
    CrossrefPubMedGoogle Scholar
  • 121 Loeffler J S, Alexander III E, Hochberg F H et al.. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas.  Int J Radiat Oncol Biol Phys. 1990;  19 1455-1462
    PubMedGoogle Scholar
  • 122 Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.  Lancet. 2002;  359 1011-1018
    CrossrefPubMedGoogle Scholar
  • 123 Stupp R, Mason W P, van den Bent M J et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.  N Engl J Med. 2005;  352 987-996
    CrossrefPubMedGoogle Scholar
  • 124 Hegi M E, Diserens A C, Gorlia T et al.. MGMT gene silencing and benefit from temozolomide in glioblastoma.  N Engl J Med. 2005;  352 997-1003
    CrossrefPubMedGoogle Scholar
  • 125 Olivi A, Grossman S A, Tatter S et al.. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.  J Clin Oncol. 2003;  21 1845-1849
    CrossrefPubMedGoogle Scholar
  • 126 Combs S E, Widmer V, Thilmann C et al.. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).  Cancer. 2005;  104 2168-2173
    CrossrefPubMedGoogle Scholar
  • 127 Combs S E, Gutwein S, Thilmann C et al.. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme.  J Neurooncol. 2005;  74 167-171
    CrossrefPubMedGoogle Scholar
  • 128 Gabayan A J, Green S B, Sanan A et al.. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.  Neurosurgery. 2006;  58 701-709
    CrossrefPubMedGoogle Scholar
  • 129 Wen P Y, Yung W K, Lamborn K R et al.. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.  Clin Cancer Res. 2006;  12 4899-4907
    CrossrefPubMedGoogle Scholar
  • 130 Yung W K, Albright R E, Olson J et al.. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.  Br J Cancer. 2000;  83 588-593
    CrossrefPubMedGoogle Scholar
  • 131 Belda-Iniesta C, Carpeno Jde C, Saenz E C et al.. Long term responses with cetuximab therapy in glioblastoma multiforme.  Cancer Biol Ther. 2006;  5 912-914
    PubMedGoogle Scholar
  • 132 Freeman III B B, Daw N C, Geyer J R et al.. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.  Cancer Invest. 2006;  24 310-317
    CrossrefPubMedGoogle Scholar
  • 133 Penne K, Bohlin C, Schneider S et al.. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.  Cancer Nurs. 2005;  28 481-486
    CrossrefPubMedGoogle Scholar
  • 134 Sathornsumetee S, Rich J N. New treatment strategies for malignant gliomas.  Expert Rev Anticancer Ther. 2006;  6 1087-1104
    CrossrefPubMedGoogle Scholar

Sujay A VoraM.D. 

Department of Radiation Oncology, Mayo Clinic Arizona

5777 East Mayo Boulevard, Phoenix, AZ 85054

      >